Literature DB >> 31682875

GIP's involvement in the pathophysiology of type 2 diabetes.

Mikkel B Christensen1, Lærke S Gasbjerg2, Sebastian M Heimbürger3, Signe Stensen2, Tina Vilsbøll4, Filip K Knop5.   

Abstract

During the past four decades derangements in glucose-dependent insulinotropic polypeptide (GIP) biology has been viewed upon as contributing factors to various parts of the pathophysiology type 2 diabetes. This overview outlines and discusses the impaired insulin responses to GIP as well as the effect of GIP on glucagon secretion and the potential involvement of GIP in the obesity and bone disease associated with type 2 diabetes. As outlined in this review, it is unlikely that the impaired insulinotropic effect of GIP occurs as a primary event in the development of type 2 diabetes, but rather develops once the diabetic state is present and beta cells are unable to maintain normoglycemia. In various models, GIP has effects on glucagon secretion, bone and lipid homeostasis, but whether these effects contribute substantially to the pathophysiology of type 2 diabetes is at present controversial. The review also discusses the substantial uncertainty surrounding the translation of preclinical data relating to the GIP system and outline future research directions.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Entero-osseous axis; GIP; Gastric inhibitory peptide; Glucagon; Glucose-dependent insulinotropic polypeptide; Gut-bone axis; Incretin; Incretin effect; Insulin secretion; Obesity

Year:  2019        PMID: 31682875     DOI: 10.1016/j.peptides.2019.170178

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

Review 1.  Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo.

Authors:  Vanessa D Sherk; Irene Schauer; Viral N Shah
Journal:  Curr Osteoporos Rep       Date:  2020-08       Impact factor: 5.096

Review 2.  GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

Authors:  Maurício Reis Pedrosa; Denise Reis Franco; Hannah Waisberg Gieremek; Camila Maia Vidal; Fernanda Bronzeri; Alexia de Cassia Rocha; Luis Gabriel de Carvalho Cara; Sofia Lenzi Fogo; Freddy Goldberg Eliaschewitz
Journal:  Curr Atheroscler Rep       Date:  2022-08-31       Impact factor: 5.967

3.  Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes.

Authors:  Mikkel B Christensen; Asger B Lund; Niklas R Jørgensen; Jens J Holst; Tina Vilsbøll; Filip K Knop
Journal:  J Endocr Soc       Date:  2020-07-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.